Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The advent of anti-HER2 agents, such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1), has significantly improved survival in metastatic HER2-positive breast cancer (BC). Multiple anti-HER2 combination regimens are recommended as first-line treatments, but the optimal choice remains unclear. This study aimed to determine the optimal first-line regimen for metastatic HER2-positive BC through a network meta-analysis of clinical trial data.

Method: The PubMed, Embase, and Cochrane Library databases and abstracts from ASCO, ESMO, and WCLC were searched up to March 16, 2023. Eligible randomized controlled trials (RCTs) were selected to analyze the progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs). Fourteen treatment regimens were ranked using the network meta-analysis and the surface under the cumulative ranking curve.

Results: Nineteen RCTs with 3,887 participants were analyzed. The taxane or paclitaxel or docetaxel + trastuzumab + pyrotinib (THPyr) regimen demonstrated the most significant PFS benefit, followed by the taxane or paclitaxel or docetaxel + trastuzumab + pertuzumab (THP) regimen. Regarding the ORR, THPyr ranked the highest, followed by THP and trastuzumab emtansin + pertuzumab (TdmP). THP offered the most favorable OS benefit. THPyr was effective in patients with HER2 3 + and hormone receptor-negative and positive status. No significant differences in safety and ≥3AEs were observed between the THPyr and other regimens.

Conclusion: The THPyr regimen might be optimal as initial treatment for patients with advanced HER2-positive BC and is likely to be approved as a new first-line treatment option.

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.jcrt_210_25DOI Listing

Publication Analysis

Top Keywords

network meta-analysis
12
optimal first-line
8
first-line regimen
8
patients advanced
8
advanced her2-positive
8
her2-positive breast
8
breast cancer
8
trastuzumab pertuzumab
8
metastatic her2-positive
8
taxane paclitaxel
8

Similar Publications

Objective: This study aimed to evaluate the effects of various physical therapy interventions on fatigue and quality of life in patients with multiple sclerosis (MS) using a network meta-analysis of randomized controlled trials (RCTs).

Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Cochrane databases through April 1, 2025. Eligible RCTs compared different exercise interventions in MS patients, focusing on fatigue and quality of life outcomes.

View Article and Find Full Text PDF

Background: Patients with atrial fibrillation (AF) with end-stage renal failure on renal replacement therapy are at high risk of stroke and bleeding, but the optimal oral anticoagulation (OAC) strategy is uncertain. To investigate the most effective OAC therapy for patients with AF on long-term dialysis.

Methods: PubMed, EMBASE and Web of Science databases were systematically searched from inception to 9 October 2024 to identify relevant studies on OAC strategy for patients with AF on long-term dialysis.

View Article and Find Full Text PDF

Background: High levels of glycated haemoglobin (HbA1c) in people with type 1 diabetes (T1D) are associated with high mortality and cardiovascular risk. Physical activity is an affordable intervention that is available to most people, but the type and amount of exercise to induce metabolic benefits in T1D are not known with certainty.

Objective: To determine the comparative effectiveness of diverse exercise modes and dosages to influence HbA1c in patients with T1D.

View Article and Find Full Text PDF

Introduction: We conducted a network meta-analysis (NMA) to compare the efficacy (primarily assessed by low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular event (CVE) incidence) and safety (total adverse events (AEs), neurocognitive events (NCEs), injection site reactions, infections, and all-cause mortality (ACM)) of different Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors placebo in the general population and solid organ transplant (SOT) recipients.

Materials And Methods: A total of 16 randomized controlled trials (RCTs) involving 79,615 patients were included. Cochrane risk of bias assessment tool evaluated the literature quality.

View Article and Find Full Text PDF

Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs).

Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment.

View Article and Find Full Text PDF